Boston – SIRION Biotech, a leading viral vector platform company known for creating high-quality viral vector solutions for industry and academic partners, recently announced its commitment to open a new office in the vicinity of Boston. The announcement was made during the 2015 BIO International Convention taking place this week in Philadelphia, Pennsylvania.
SIRION is working with the Massachusetts Life Sciences Center (MLSC) to locate lab and office space for the company, which will prove to be a pivotal step in SIRION’s U.S. expansion. SIRION’s office in the Boston area will allow direct access to Massachusetts’ vibrant life sciences community, which includes an increasing number of biotechnology companies and academic researchers working to develop gene therapies and vaccines for a range of diseases.
“We appreciate the assistance from Massachusetts Life Sciences Center in helping us begin building our U.S. operations in the Boston area, during such an exciting time in our industry,” said Dieter Lingelbach, chief operating officer of SIRION Biotech. “We are a growing company, planning to build on the success we’ve had in Europe, Israel, and Japan, as we collaborate with many companies pioneering gene therapies.”
“We are pleased to welcome SIRION to Massachusetts, where the gene therapy space continues to receive significant attention from stakeholders in the life sciences due to its potential to cure a variety of diseases,” said Angus McQuilken, MLSC vice president for communications and marketing. “SIRION will be a great addition to this growing part of the Massachusetts life sciences ecosystem.”
“We’re so excited to welcome SIRION to the Massachusetts super cluster and know it is going to hit the ground running as a valuable partner to the companies and organizations here,” said Robert K. Coughlin, president and CEO at MassBio.
SIRION provides customizable versions of all three major viral vector types, adenovirus (AV), adeno-associated virus (AAV), and lentivirus (LV), and offers expertise in transduction of various cell lines, an essential piece of all genetic applications. SIRION’s high-quality products and well-established processes, coupled with its commitment to addressing each client’s unique needs, have established the company as a leader in viral vector solutions. SIRION’s expertise in custom viral vector solutions and process development makes SIRION an ideal collaborative partner.
“Producing products of the highest quality, purity, and yield is of paramount importance and is also one of the biggest challenges,” said Dr. Christian Thirion, founder and CTO. “Our suite of proprietary products and services enables us to provide the highest quality tools for downstream applications in gene therapy and vaccine development.”
“I am very pleased that our work to attract life sciences investment — particularly in viral vector manufacturing — is evident to companies like Sirion,” said Senator Michael Rodriques (D-Westport). “This is a great opportunity for Massachusetts, and during our meeting with the company I spoke to them about all that Fall River has to offer as a potential location for this growing company’s U.S. operations.”